IntegraGen announces EUR 2 million Equity Investment by DSM Venturing, Alongside R&D Partnership with DSM Personalized Nutrition Group.

PARIS -- IntegraGen, the personalized healthcare company focused on the development and commercialization of genetic tests for complex diseases, has announced that DSM Venturing, the corporate venturing arm of Royal DSM N.V. has invested e-2M in the Company. In addition, it has entered into a collaborative R&D partnership with the DSM Personalized Nutrition Group for the development of molecular diagnostic products for personalized healthcare.

IntegraGen is focused on the development of diagnostic and prognostic genetic tests for a range of complex diseases using its proprietary technology platform for gene identification (Genome HIPe). Under the terms of the agreement with DSM, the Company will receive upfront fees, license fees and funding for research and development. In addition, IntegraGen will be eligible for royalties upon commercialization. Each company will retain rights to the intellectual property portfolio developed under the collaboration in their areas of focus, being diagnostics and medicines for IntegraGen and nutrition for DSM.

Dr Jan Mous, President and CEO of IntegraGen, said: eIuThe DSM collaboration enhances our position in the personalized medicine market, promising to further expand our patent portfolio and commercialized products in the areas of obesity and metabolic disorders. The DSM relationship is a testimonial to the value of IntegraGeneIUs intellectual property and capabilities for identifying genes of interest to IntegraGen and partners in the diagnostics and personalized healthcare markets.eIN

DSM found in IntegraGen a partner with world-class capabilities in personalized medicine. DSM has not only recognised the CompanyeIUs first-class research capability and access to targeted patient collections, but also the unparalleled competitive advantage of its technology, Genome HIPe, which provides the ability to rapidly identify genes associated with any complex genetic disorders, such as obesity and type 2 diabetes.

Rob van Leen, Chief Innovation Officer at DSM said: eIuWe recognize that IntegraGeneIUs innovative and pioneering technologies in the field of personalized healthcare have applications across the full spectrum of healthcare from medical treatment to lifestyle management. We are delighted to enter into a partnership with a company with such a powerful technology, which, associated with IntegraGeneIUs expertise in the medical/pharma application of personalized healthcare, will allow us to rapidly realise the commercial potential of our weight management programmes, an important area within the emerging field of Personalized Nutrition.eIN

Notes to editors:

About IntegraGen

IntegraGen is a pioneer in the field of predictive healthcare. The company uses its unique genomic analysis expertise to identify genes associated with complex diseases and commercializes molecular diagnostic tests to enable individualized diagnosis, prevention and treatment.

IntegraGeneIUs proprietary gene mapping technology GenomeHIPe provides fast, reliable, and cost-effective discovery of genetic loci. Paired with strong biostatistics, bioinformatics and fine mapping genotyping capabilities, IntegraGen has successfully identified and patented genes associated with early and late onset diseases. Efforts are currently focused on Type-2 Diabetes, Obesity, Autism and Bi-Polar Disorder. Clinical trials for the companyeIUs first diagnostics test, based on internally identified genes, are planned for Q1 2007.

IntegraGen has two commercial operations. Diagnostic testing and counselling services are offered through a Diabetes Competence Center, based in Bonn, Germany. The Company has recently received accreditation under ISO Standard 17025 for performing human genetic analyses in this Centre. A Genetic Services business, operating out of the companyeIUs headquarters in Evry, France, provides customized genotyping and BAC array services to the research community.

In 2005, IntegraGen announced the successful closing of its second financing round raising e-8 million ($9.6 million), bringing the total capital raised by IntegraGen to date to e-20 million ($24million). The international syndicate of investors included CDC Entreprises Innovation, AGF Private Equity, Bioam, SGAM Alternative Investments, Baytech Venture Capital, and Avenir Finance Gestion.

Founded in July 2000, IntegraGen has 34 employees and is based in the French Genopole of Evry, near Paris, France, and in Bonn, Germany. More information can be found at www.integragen.com

About DSM Venturing

DSM Venturing is an active investor in start-up companies and Venture Capital Funds in DSMeIUs strategic growth fields Nutrition, Pharma and Performance Materials. DSM Venturing's mission is to explore emerging markets and technologies in these strategic growth fields in order to enhance DSM's product portfolio and create value. DSM Venturing also plays an active role in the development of several new DSM business opportunities in the so-called emerging business areas Biomedical Materials, Industrial (White) Biotechnology, Specialty Packaging and Personalized Nutrition. For more information about DSM Venturing see www.dsm-venturing.com.